Great news, finally.
I was wondering about what numbers we could be seeing with both the Eisai partnership and the ERT partnership.
I understand that there is huge potential here, but it's not as if the company has been profitable, right? How should one think about it?
If we divide those $45 Million from Eisai by 10 years, we're talking about $4,5 Million per year. Let's say that it's all profit and slap a 20x multiple on it. That would mean a AUD$126 Million marketcap. The current marketcap is $206 Million, so Mr Market is ascribing a AUD$80 Million value for the Clinical Trials and Research segments.
Is this too low? The administration costs have been consistently higher (or just a bit lower) than the operating profit from the Clinical Trials segment, so...
If Aducanumab doesn't go forward, should we expect a decline in Clinical Trials revenue?
Cheers
- Forums
- ASX - By Stock
- CGS
- Putting numbers on it
CGS
cogstate ltd
Add to My Watchlist
3.41%
!
$1.82

Putting numbers on it
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.82 |
Change
0.060(3.41%) |
Mkt cap ! $308.9M |
Open | High | Low | Value | Volume |
$1.77 | $1.86 | $1.76 | $400.6K | 221.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2522 | $1.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.82 | 3170 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2522 | 1.800 |
1 | 14000 | 1.780 |
1 | 278 | 1.770 |
2 | 2210 | 1.750 |
1 | 8243 | 1.740 |
Price($) | Vol. | No. |
---|---|---|
1.820 | 3170 | 1 |
2.100 | 5560 | 3 |
2.150 | 537 | 1 |
2.200 | 5300 | 1 |
2.300 | 600 | 2 |
Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
Featured News
CGS (ASX) Chart |